Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Rüfer, Axel; Angermann, Hubert; Benz, Rudolf; Bonadies, Nicolas; Calderoni, Antonello; Cantoni, Nathan; Efthymiou, Anna; Escher, Robert; Favre, Geneviève; Friess, Dorothea; Gschwend, Andreas; Himmelmann, Andreas; Holbro, Andreas; Keller, Peter M.; Kouroupi, Eirini; Lehmann, Thomas; Pedarnig, N; Rigamonti, Véronique; Samii, Kaveh; Schmidt, Adrian; Schäfer, Hans-Peter; Sperb, Roland; Stüssi, Georg; Winkler, Annette; Zenhäusern, Reinhard; Goede, Jeroen S.

doi:10.1097/hs9.0000000000000741

HemaSphere

2022

DOI: 10.1097/hs9.0000000000000741

|View full text |Cite

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Axel Rüfer

Hubert Angermann²,

Rudolf Benz

et al.

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current practice in the real-world setting, in regard to patients with MDS-del(5q), is heterogeneous, in terms of both treatment initiation with lenalidomide and disease monitoring [ 12 , 13 ]. The observations from the current study underline the need for monitoring of mutations both at diagnosis (preferably using highly sensitive assays) and during the disease course, in patients with MDS-del(5q), regardless of specific treatment.…”

mentioning

confidence: 99%

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Abdallah,

Reichard,

Gangat

et al. 2024

Blood Cancer J.

View full text Add to dashboard Cite

mentioning

confidence: 99%

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Abdallah,

Reichard,

Gangat

et al. 2024

Blood Cancer J.

View full text Add to dashboard Cite

Clinical decision-making and treatment of myelodysplastic syndromes

Hellström-Lindberg,

Kröger

2023

Blood

View full text Add to dashboard Cite

The myelodysplastic syndromes (MDS) constitute a profoundly heterogeneous myeloid malignancy with a common origin in the hemopoietic stem cell compartment. Consequently, patient management and treatment are as heterogeneous. Decision-making includes identifying risk, symptoms, and options for the individual patient and to make a risk-benefit analysis. The only potential cure is allogeneic stem cell transplantation and albeit the fraction of transplanted MDS patients increase over time due to a better management and increased donor availability a majority are not eligible for this intervention. Current challenges encompass to decrease the relapse risk, the main cause of HSCT failure. Hypomethylating agents (HMA) constitute first-line treatment for higher-risk MDS. Combinations with other drugs as first-line treatment has to date not proven more efficacious than monotherapy, although combinations approved for acute myeloid leukemia, including venetoclax currently are under evaluation and often used as rescue treatment. The treatment goal for lower-risk MDS is to improve cytopenia, mainly anemia, quality-of-life, and possibly overall survival. Erythropoiesis-stimulating agents (ESAs) constitute first-line treatment for anemia and have better and more durable responses if initiated before the onset of a permanent transfusion need. Treatment in case of ESA failure or ineligibility should be tailored to the main disease mechanism; immunosuppression for hypoplastic MDS without high-risk genetics, lenalidomide for low-risk del(5q) MDS, and luspatercept for MDS with ring sideroblasts. Approved therapeutic options are still more scarce for MDS than for most other hematological malignancies. Better tools to match disease biology with treatment, i.e. applied precision medicine is needed to improve patient outcome.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Cited by 2 publications

References 8 publications

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?

Clinical decision-making and treatment of myelodysplastic syndromes

Contact Info

Product

Resources

About